Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 7:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 153 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Head and Neck Cancer, Diffuse Large B-cell Lymphoma
Interventions
PET/CT, Laboratory Testing, Safety Testing, Immunohistochemistry staining, F-18-ISO
Radiation · Other · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Completed No phase listed Observational

FDG PET/CT in Breast Cancer Bone Mets

NCT01996046
Conditions
Estrogen Receptor Positive Breast Cancer, Bone Metastases
Interventions
FDG PET/CT scan
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
F-18 Fluoroestradiol, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Metastatic Breast Cancer
Interventions
Radiation therapy, Study Drug
Radiation · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Survey Administration, Volume Modulated Arc Therapy, Hippocampal-Avoidance Craniospinal Irradiation
Procedure · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Conditions
Breast Cancer, Ductal Carcinoma in Situ - Category
Interventions
(18F)FES, Gadobenate dimeglumine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Active, not recruiting Not applicable Interventional Results available

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

NCT01093612
Conditions
Breast Cancer, Stage IV Breast Cancer
Interventions
positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy, Immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis
Procedure · Radiation · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Cancer
Interventions
18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
laboratory biomarker analysis, pharmacological study, questionnaire administration, fluorine F 18-clevudine, positron emission tomography/computed tomography
Other · Radiation · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 75 more
Conditions
Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma
Interventions
18F-fluorofuranylnorprogesterone, Liquid Biopsy, Positron Emission Tomography/Computed Tomography
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
Interventions
Iodine-124, PET/CT with Iodine-124
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Stanford, California
Active, not recruiting Phase 1 Interventional

Testing a New Imaging Agent to Identify Cancer

NCT04692831
Conditions
HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer
Interventions
89Zr-ss-pertuzumab PET/CT
Combination Product
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Triple Negative Breast Neoplasms
Interventions
Docetaxel, Carboplatin, FDG-PET/MR
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
124 PET/CT imaging, Na134I, Tri-iodothyronine
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Stanford, California
Conditions
Breast Cancer, Breast Neoplasm
Interventions
[18F]ISO-1
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
BPET/DBT imaging, 18F-FES
Device · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Bone Metastases, HER2-positive Breast Cancer, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Soft Tissue Metastases, Stage IV Breast Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, trastuzumab, copper Cu 64-DOTA-trastuzumab, ado-trastuzumab emtansine, laboratory biomarker analysis
Radiation · Procedure · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Breast Carcinoma, Estrogen Receptor Positive
Interventions
Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging, Positron Emission Tomography, Investigational software and coils in PET/MR scan
Drug · Procedure · Device
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Breast Cancer
Interventions
Avelumab, Endocrine therapy, Palbociclib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Conditions
Metastatic Breast Cancer
Interventions
18F Fluoroestradiol Radiopharmaceutical with PET/CT
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Flagstaff, Arizona • Cerritos, California • Duarte, California + 20 more
Conditions
Breast Cancer
Interventions
PET/MR
Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
CT, 18F-FLT, PET
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more